CSL (OTCMKTS:CSLLY) Shares Gap Down – Time to Sell?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped down before the market opened on Tuesday . The stock had previously closed at $31.70, but opened at $30.23. CSL shares last traded at $31.67, with a volume of 482 shares traded.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CSLLY. Citigroup downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Canaccord Genuity Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Jefferies Financial Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Finally, Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Five research analysts have rated the stock with a Hold rating, According to MarketBeat.com, CSL presently has an average rating of “Hold”.

CSL Price Performance

The firm’s 50-day moving average price is $24.59 and its 200 day moving average price is $24.42. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.